Evidence map›Paper›PMID 26240484›Full record

ArticleJournal of Korean medical science2015

Clinical Significance of Substaging and HER2 Expression in Papillary Nonmuscle Invasive Urothelial Cancers of the Urinary Bladder.

So Dug Lim, Yong Mee Cho, Gyu-Seog Choi, Hyung Kyu Park, Sung Hyun Paick, Wook Youn Kim, Soo-Nyung Kim, Ghilsuk Yoon

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Korean medical science, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 3 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Human epidermal growth factor receptor 2 (Arab journal of urology · 2020
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

So Dug LimDepartment of Pathology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.
Yong Mee ChoDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Gyu-Seog ChoiColorectal Cancer Center, Kyungpook National University Medical Center, Kyungpook National University School of Medicine, Daegu, Korea.
Hyung Kyu ParkDepartment of Pathology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.
Sung Hyun PaickDepartment of Urology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.
Wook Youn KimDepartment of Pathology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.
Soo-Nyung KimDepartment of Obstetrics and Gynecology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.
Ghilsuk YoonDepartment of Pathology, Kyungpook National University Medical Center, Kyungpook National University School of Medicine, Daegu, Korea.
Konkuk University Medical Center · KRKyungpook National University Medical Center · KRUlsan College · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The study aimed to verify the prognostic utility, therapeutic application and clinical benefits of tumor substaging and HER2 status in papillary non-muscle invasive bladder cancer (NMIBC). Select NMIBC transurethral resection specimens from 141 patients were used to construct tissue microarrays for assessing the substaging, HER2 protein expression by immunohistochemistry (HER2-IHC) and gene amplification by dual-color silver in situ hybridization (HER2-SISH). Substages were identified by the differing depth of tumor invasion (pTa / pT1a / pT1b / pT1c). HER2 protein expression was semiquantitatively analyzed and grouped into negative (score 0, 1+) and positive (score 2+, 3+). Other clinicopathological variables were also investigated. For NMIBC, HER2-IHC and HER2-SISH showed positive results in 6/141 (4.3%) and 4/141 (2.8%) respectively, which correlated well with tumor substaging. In multivariate analysis, substaging, HER2-IHC, and HER2-SISH were found to be independent predictors of progression-free survival (P < 0.001, P < 0.001, P = 0.031). HER2-IHC was the sole independent predictor of recurrent free survival in NMIBC (P = 0.017). It is suggested that tumor substaging and HER2 status are independent predictive markers for tumor progression or recurrence, and thus could be included in diagnostic and therapeutic management for NMIBC.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, PapillaryCarcinoma, Transitional CellErb-b2 Receptor Tyrosine KinasesFemaleHumansMaleMiddle AgedNeoplasm StagingReproducibility of ResultsSensitivity and SpecificityUrinary Bladder NeoplasmsYoung AdultBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesBladder CancerCancer StagingHER2 GeneImmunohistochemistryIn Situ Hybridization

Identifiers

PMID26240484
PMCPMC4520937
OpenAlexW1895651016

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.